evommune.com

▸ir68 pages

Accessibility Request Form :: Evommune, Inc. (EVMN)

Disclaimer :: Evommune, Inc. (EVMN)

Privacy Policy :: Evommune, Inc. (EVMN)

rss-news-feed

Accessibility Statement :: Evommune, Inc. (EVMN)

▸financial-information31 pages

June 29, 2026 - EX-99.1 - 8-K: Current report | Evommune, Inc. (EVMN)

July 16, 2026 - JOINT FILING AGREEMENT - SCHEDULE 13G: Statement of Beneficial Ownership by Certain Investors | Evommune, Inc. (EVMN)

July 16, 2026 - SCHEDULE 13G: Statement of Beneficial Ownership by Certain Investors | Evommune, Inc. (EVMN)

June 24, 2026 - Patel Jeegar Pravinkumar - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)

June 29, 2026 - 8-K: Current report | Evommune, Inc. (EVMN)

… 26 more pages

▸news-events21 pages

Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress :: Evommune, Inc. (EVMN)

evommune-announces-positive-top-line-datafrom-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update :: Evommune, Inc. (EVMN)

Evommune Announces Pricing of its Initial Public Offering :: Evommune, Inc. (EVMN)

Evommune Announces Commencement of Initial Public Offering :: Evommune, Inc. (EVMN)

… 16 more pages

▸stock-data3 pages

Analyst Coverage :: Evommune, Inc. (EVMN)

Historical Data :: Evommune, Inc. (EVMN)

Quote & Chart :: Evommune, Inc. (EVMN)

… 8 more pages

▸wp-content17 pages

▸uploads17 pages

Privacy Statement

Evommune_GUF_2024_EVO756-HV001_Oral_Presentation_22Nov2024_2

evommune_ahs_presentation_role_of_mrgprx2_in_migraine-pdf

2026 SID EVO301 poster FINAL

Slide 1

… 12 more pages

view all 17 pages

▸team19 pages

Gregory S. Moss, Esq. - Evommune

Janice Drew, M.P.H. - Evommune

David E. Cohen, M.D., M.P.H. - Evommune

Jeegar Patel, Ph.D. - Evommune

J. Mark Jackson, M.D. - Evommune

… 14 more pages